Reaching Others University at Buffalo - The State University of New York
Skip to Content
UB Reporter

Research News

Sharing
10/23/14

UB chemist Jason Benedict has organized a crystal-growing challenge for K-12 students and the "biggest, nicest” crystals win.

Bling, bling!
10/23/14

UB chemist Jason Benedict has organized a crystal-growing challenge for K-12 students and the "biggest, nicest” crystals win.

More companies join START-UP NY at UB
10/23/14

Five more companies will set up shop on or near the UB campuses under START-UP NY, the innovative tax-incentive program created by Gov. Andrew M. Cuomo.

Reducing hazmat risk
10/20/14

UB researcher Changhyun Kwon has received a NSF CAREER Award to build a routing simulator that would reduce catastrophic hazardous materials accidents.

Architect Barbie, three years later
10/16/14

Architect Barbie co-creaters Despina Stratigakos and Kelly Hayes McAlonie are traveling to Washington, D.C., to talk about how the gender debate in the profession has changed.

Continuing HIV drug development
10/16/14

The School of Pharmacy and Pharmaceutical Sciences has received three grants totaling $3.85 million from the National Institutes of Health for the Translational Pharmacology Research Core and its HIV Clinical Pharmacology Research Program.

RENEW awards seed funding
10/16/14

Four research projects have received seed funding under RENEW, UB’s new interdisciplinary environmental research initiative.

Transforming patient care
10/16/14

In response to new 'game-changing' hepatitis C treatments, UB has launched a clinical care center to advance research, clinical management and education on liver disease.

Food (policy) back on the table
10/16/14

A new UB study outlines seven factors that led one of America’s poorest cities to embrace farming, urban chickens and more

Extending battery life
10/13/14

Three UB research groups have received a combined $1.3 million in federal grants to improve smartphone energy management.

Rights acquired to spider-venom drug
10/9/14

A clinical-stage biopharmaceutical company has acquired the rights to a drug that UB scientists have begun developing for Duchenne muscular dystrophy, a common, fatal genetic disease affecting young boys.